| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Chen,Zhi-Quan | Chairman | 3.52% | ZHANG CHUN INVESTMENT CO., LTD. |
| Chen,Ya-Qi | Director | 27.28% | OBI PHARMA, INC. |
| Ding,Wan-Fang | Director | 27.28% | OBI PHARMA, INC. |
| He,Zheng-Hong | Director | 0.76% | |
| Lin,Shi-Ming | Independent Director | 0.00% | |
| Wang,Hui-Jun | Independent Director | 0.00% | |
| Qiu,Cong-Zhi | Independent Director | 0.00% |
Change Company Name to AP BIOSCIENCES INC.
2024/05/17
Change Company Name to YUANXIANG BIOTECHNOLOGY CO., LTD. (FORMER NAME: YUANXIANG LIFE TECHNOLOGY CO., LTD.)
2022/06/06
Change Company Name to AP BIOSCIENCES INC.
2021/11/10
Change Capital to 1,000,000,000
2021/11/10
Change Person in Charge to Chen,Zhi-Quan
2021/06/11
Change Person in Charge to Lin,Hong-Da
2019/02/14
Change Capital to 300,000,000
2018/11/15
Change Person in Charge to Huang,Xiu-Mei
2018/03/30
Change Capital to 100,000,000
2016/04/18
Change Capital to 90,000,000
2014/05/29
下載完整報告查看完整數據
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 0 | 32,253 | 0 |
| Operating cost | 0 | 0 | 0 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 0 | 32,253 | 0 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 0 | 32,253 | 0 |
| Operating expenses | 233,379 | 379,731 | 297,496 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -233,379 | -347,478 | -297,496 |
| Non-operating income and expenses | 7,108 | 8,183 | 8,961 |
| Net profit (loss) before tax | -226,271 | -339,295 | -288,535 |
| Income tax expense (benefits) | 0 | 0 | 0 |
| Net profit (loss) of ongoing business for the current period | -226,271 | -339,295 | -288,535 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -226,271 | -339,295 | -288,535 |
| Other comprehensive profit (loss), net | 436 | - | - |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -225,835 | -339,295 | -288,535 |
| Net profit (loss) attributable to owners of parent company | -226,271 | - | - |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | -225,835 | - | - |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | -3 | -5 | -5 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | -195,878 | - | - |
| Net cash inflows (outflows) from investing activities | 360,098 | - | - |
| Net cash inflow (outflow) from financing activities | 1,197,825 | - | - |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 436 | - | - |
| Increase (decrease) in cash and cash equivalents in the current period | 1,362,481 | - | - |
| Beginning balance of cash and cash equivalents | 278,607 | - | - |
| Ending balance of cash and cash equivalents | 1,641,088 | - | - |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 1,770,155 | 765,642 | 1,094,039 |
| Non-current asset | 119,556 | 125,114 | 9,140 |
| Total asset | 1,889,711 | 890,756 | 1,103,179 |
| Current liability | 32,793 | 30,875 | 4,519 |
| Non-current liability | 70,270 | 75,775 | - |
| Total liability | 103,063 | 106,650 | 4,519 |
| share capital | 848,709 | 647,479 | 647,479 |
| Equity - secruity token | - | - | - |
| capital reserve | 1,163,774 | 475,922 | 739,716 |
| retained earning | -226,271 | -339,295 | -288,535 |
| Other equity | 436 | - | - |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 1,786,648 | - | - |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 1,786,648 | 784,106 | 1,098,660 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 21 | 12 | 16 |
